Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates.

Torres MDT, Pedron CN, Higashikuni Y, Kramer RM, Cardoso MH, Oshiro KGN, Franco OL, Silva Junior PI, Silva FD, Oliveira Junior VX, Lu TK, de la Fuente-Nunez C.

Commun Biol. 2018 Dec 7;1:221. doi: 10.1038/s42003-018-0224-2. eCollection 2018.

2.

Activation of Toll-Like Receptor 9 Impairs Blood Flow Recovery After Hind-Limb Ischemia.

Nishimoto S, Aini K, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Kusunose K, Yamada H, Soeki T, Shimabukuro M, Sata M.

Front Cardiovasc Med. 2018 Oct 16;5:144. doi: 10.3389/fcvm.2018.00144. eCollection 2018.

3.

Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice.

Ganbaatar B, Fukuda D, Salim HM, Nishimoto S, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Soeki T, Sata M.

Atherosclerosis. 2018 Aug;275:124-132. doi: 10.1016/j.atherosclerosis.2018.05.053. Epub 2018 May 31.

PMID:
29902700
4.

Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury.

Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M.

Eur J Pharmacol. 2018 Feb 5;820:222-228. doi: 10.1016/j.ejphar.2017.12.037. Epub 2017 Dec 18.

PMID:
29269019
5.

Advancing therapeutic applications of synthetic gene circuits.

Higashikuni Y, Chen WC, Lu TK.

Curr Opin Biotechnol. 2017 Oct;47:133-141. doi: 10.1016/j.copbio.2017.06.011. Epub 2017 Aug 17. Review.

PMID:
28750201
6.

Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.

Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M.

Vascul Pharmacol. 2017 Sep;96-98:19-25. doi: 10.1016/j.vph.2017.03.003. Epub 2017 Mar 27.

PMID:
28347868
7.

Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation.

Takashima A, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, Yagi S, Yamada H, Soeki T, Wakatsuki T, Taketani Y, Shimabukuro M, Sata M.

Atherosclerosis. 2016 Nov;254:142-150. doi: 10.1016/j.atherosclerosis.2016.10.002. Epub 2016 Oct 5.

PMID:
27744130
8.

Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance.

Nishimoto S, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Murata C, Kim-Kaneyama JR, Sato F, Bando M, Yagi S, Soeki T, Hayashi T, Imoto I, Sakaue H, Shimabukuro M, Sata M.

Sci Adv. 2016 Mar 25;2(3):e1501332. doi: 10.1126/sciadv.1501332. eCollection 2016 Mar.

9.

Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.

Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M.

Vascul Pharmacol. 2016 Apr;79:16-23. doi: 10.1016/j.vph.2015.08.011. Epub 2015 Aug 13.

PMID:
26277250
10.

Giant left atrial myxoma that caused mitral valve obstruction and pulmonary hypertension.

Shimizu Y, Itoda Y, Higashikuni Y, Kadowaki Y, Saito A, Fujita H, Yamashita H, Watanabe M, Ono M, Komuro I.

Int J Cardiol. 2015 Nov 15;199:38-9. doi: 10.1016/j.ijcard.2015.06.158. Epub 2015 Jul 2. No abstract available.

PMID:
26186627
11.

Pioglitazone Reduces Vascular Lipid Accumulation in Angiotensin II-Induced Hypertensive Rat.

Sakamoto A, Higashikuni Y, Hongo M, Imai Y, Koike K, Nagai R, Komuro I, Ishizaka N.

J Atheroscler Thromb. 2015;22(12):1225-34. doi: 10.5551/jat.28977. Epub 2015 Jul 3.

12.

Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.

Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, Yagi S, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Sata M.

Atherosclerosis. 2015 Oct;242(2):639-46. doi: 10.1016/j.atherosclerosis.2015.03.023. Epub 2015 Mar 19.

PMID:
25817329
13.

Impact of the distance from the stent edge to the residual plaque on edge restenosis following everolimus-eluting stent implantation.

Takahashi M, Miyazaki S, Myojo M, Sawaki D, Iwata H, Kiyosue A, Higashikuni Y, Tanaka T, Fujita D, Ando J, Fujita H, Hirata Y, Komuro I.

PLoS One. 2015 Mar 16;10(3):e0121079. doi: 10.1371/journal.pone.0121079. eCollection 2015.

14.

Midterm follow-up after retrievable inferior vena cava filter placement in venous thromboembolism patients with or without malignancy.

Myojo M, Takahashi M, Tanaka T, Higashikuni Y, Kiyosue A, Ando J, Fujita H, Komuro I, Hirata Y.

Clin Cardiol. 2015 Apr;38(4):216-21. doi: 10.1002/clc.22377. Epub 2015 Mar 6.

15.

Endothelial PGC-1α mediates vascular dysfunction in diabetes.

Sawada N, Jiang A, Takizawa F, Safdar A, Manika A, Tesmenitsky Y, Kang KT, Bischoff J, Kalwa H, Sartoretto JL, Kamei Y, Benjamin LE, Watada H, Ogawa Y, Higashikuni Y, Kessinger CW, Jaffer FA, Michel T, Sata M, Croce K, Tanaka R, Arany Z.

Cell Metab. 2014 Feb 4;19(2):246-58. doi: 10.1016/j.cmet.2013.12.014.

16.

Cardiac compression by massive mediastinal haematoma due to bleeding from the ectopic bronchial artery.

Muraoka H, Higashikuni Y, Ando J, Komuro I.

Eur Heart J. 2014 Jun 14;35(23):1567. doi: 10.1093/eurheartj/eht520. Epub 2013 Dec 18. No abstract available.

PMID:
24357504
17.

HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9.

Hirata Y, Kurobe H, Higashida M, Fukuda D, Shimabukuro M, Tanaka K, Higashikuni Y, Kitagawa T, Sata M.

Atherosclerosis. 2013 Dec;231(2):227-33. doi: 10.1016/j.atherosclerosis.2013.09.010. Epub 2013 Oct 2.

PMID:
24267232
18.

Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation.

Higashikuni Y, Tanaka K, Kato M, Nureki O, Hirata Y, Nagai R, Komuro I, Sata M.

J Am Heart Assoc. 2013 Nov 18;2(6):e000267. doi: 10.1161/JAHA.113.000267.

20.

The ATP-binding cassette transporter ABCG2 protects against pressure overload-induced cardiac hypertrophy and heart failure by promoting angiogenesis and antioxidant response.

Higashikuni Y, Sainz J, Nakamura K, Takaoka M, Enomoto S, Iwata H, Tanaka K, Sahara M, Hirata Y, Nagai R, Sata M.

Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):654-61. doi: 10.1161/ATVBAHA.111.240341. Epub 2011 Nov 23.

PMID:
22116099
21.

Vascular antispastic medication should take priority over other antihypertensives after coronary artery bypass grafting using a radial artery conduit.

Kitamura T, Motomura N, Higashikuni Y, Ono M.

Interact Cardiovasc Thorac Surg. 2011 Dec;13(6):679-81. doi: 10.1510/icvts.2011.280537. Epub 2011 Sep 4.

PMID:
21891799
22.

Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.

Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, Nagai R, Sata M.

Hypertens Res. 2012 Jan;35(1):62-9. doi: 10.1038/hr.2011.136. Epub 2011 Aug 11.

PMID:
21833001
23.

The ATP-binding cassette transporter BCRP1/ABCG2 plays a pivotal role in cardiac repair after myocardial infarction via modulation of microvascular endothelial cell survival and function.

Higashikuni Y, Sainz J, Nakamura K, Takaoka M, Enomoto S, Iwata H, Sahara M, Tanaka K, Koibuchi N, Ito S, Kusuhara H, Sugiyama Y, Hirata Y, Nagai R, Sata M.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2128-35. doi: 10.1161/ATVBAHA.110.211755. Epub 2010 Sep 9.

PMID:
20829509
24.

Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease.

Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y.

J Thromb Haemost. 2010 Jun;8(6):1170-5. doi: 10.1111/j.1538-7836.2010.03833.x. Epub 2010 Mar 3.

25.

Difference of culprit plaque composition between patients with and without pre-infarction angina: an intravascular ultrasound radiofrequency analysis.

Higashikuni Y, Tanabe K, Tanimoto S, Aoki J, Yamamoto H, Nakazawa G, Chihara R, Onuma Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K.

EuroIntervention. 2009 Aug;5(3):363-9.

PMID:
19736162
26.

Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice.

Nakamura K, Koibuchi N, Nishimatsu H, Higashikuni Y, Hirata Y, Kugiyama K, Nagai R, Sata M.

Hypertens Res. 2008 Oct;31(10):1953-61. doi: 10.1291/hypres.31.1953.

PMID:
19015603
27.

Impact of culprit plaque composition on the no-reflow phenomenon in patients with acute coronary syndrome: an intravascular ultrasound radiofrequency analysis.

Higashikuni Y, Tanabe K, Tanimoto S, Aoki J, Yamamoto H, Nakazawa G, Chihara R, Onuma Y, Ohtsuki S, Yagishita A, Yachi S, Nakajima H, Hara K.

Circ J. 2008 Aug;72(8):1235-41.

28.

Efficacy of culprit plaque assessment by 64-slice multidetector computed tomography to predict transient no-reflow phenomenon during percutaneous coronary intervention.

Nakazawa G, Tanabe K, Onuma Y, Yachi S, Aoki J, Yamamoto H, Higashikuni Y, Yagishita A, Nakajima H, Hara K.

Am Heart J. 2008 Jun;155(6):1150-7. doi: 10.1016/j.ahj.2008.01.006. Epub 2008 Mar 28.

PMID:
18513532
29.

Sirolimus-eluting stents suppress neointimal formation irrespective of metallic allergy.

Nakazawa G, Tanabe K, Aoki J, Onuma Y, Higashikuni Y, Yamamoto H, Ohtsuki S, Yachi S, Yagishita A, Nakajima H, Hara K.

Circ J. 2008 Jun;72(6):893-6.

30.

Relationship between blood pressure and chronic kidney disease in the Japanese population: the lower the better even in individuals without hypertension?

Higashikuni Y, Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M.

Hypertens Res. 2008 Feb;31(2):213-9. doi: 10.1291/hypres.31.213.

PMID:
18360039
31.

Right aortic arch with mirror image branching and vascular ring.

Higashikuni Y, Nagashima T, Ishizaka N, Kinugawa K, Hirata Y, Nagai R.

Int J Cardiol. 2008 Oct 30;130(1):e53-5. Epub 2007 Sep 21.

PMID:
17889381
32.

Giant left coronary artery aneurysm in a patient with mixed connective tissue disease.

Asada K, Hatano M, Takeda N, Higashikuni Y, Saito K, Ishizaka N, Hirata Y, Nagai R.

Intern Med. 2007;46(15):1267-8. Epub 2007 Aug 2. No abstract available.

33.

Interleukin-6-producing giant cell carcinoma of the lung with multicentric Castleman's disease-like presentation.

Higashikuni Y, Mori M, Kino H.

Intern Med. 2007;46(10):669-73. Epub 2007 May 24.

34.

Relationship between coronary artery remodeling and plaque composition in culprit lesions: an intravascular ultrasound radiofrequency analysis.

Higashikuni Y, Tanabe K, Yamamoto H, Aoki J, Nakazawa G, Onuma Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K.

Circ J. 2007 May;71(5):654-60.

35.

Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation.

Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama T, Onuma Y, Higashikuni Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K.

Catheter Cardiovasc Interv. 2007 Feb 15;69(3):380-6.

PMID:
17195199
36.

Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents.

Nakazawa G, Tanabe K, Aoki J, Yamamoto H, Higashikuni Y, Onuma Y, Yachi S, Nakajima H, Hara K.

Catheter Cardiovasc Interv. 2007 May 1;69(6):808-14.

PMID:
17191206
37.

Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice.

Gaku N, Kengo T, Aoki J, Onuma Y, Yamamoto H, Higashikuni Y, Nakajima H, Hara K.

Circ J. 2006 Nov;70(11):1367-71.

38.

Prevalence of carotid artery stenosis in patients with coronary artery disease in Japanese population.

Tanimoto S, Ikari Y, Tanabe K, Yachi S, Nakajima H, Nakayama T, Hatori M, Nakazawa G, Onuma Y, Higashikuni Y, Yamamoto H, Tooda E, Hara K.

Stroke. 2005 Oct;36(10):2094-8. Epub 2005 Sep 22.

PMID:
16179563
39.

Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.

Higashikuni Y, Sata M, Nagai R.

Acta Cardiol. 2005 Feb;60(1):77-9.

PMID:
15779859

Supplemental Content

Loading ...
Support Center